Hematology-Oncology
Latest news
316 articles · 20 / page
Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults
A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and
Enasidenib plus Venetoclax Shows Promising Activity in IDH2‑Mutant Relapsed/Refractory AML — ENAVEN‑AML Phase 1b/2 Results
The ENAVEN‑AML trial reports that enasidenib combined with venetoclax is feasible and active in relapsed/refractory IDH2‑mutant AML, achieving a 62% overall response rate with manageable toxicity but substantial infectious complications in
IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity
A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ
Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Distinct Clinical Entity
Lupuslike manifestations linked with MDS and CMML differ greatly from classic lupus, featuring unique clinical and molecular traits and often requiring clone-directed treatment rather than standard lupus therapies.
Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes
A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGA
Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort
In a population-based Medicare cohort, oncologists preferentially selected higher-clinical-benefit cancer treatments; provider billing margin was not associated with treatment choice, suggesting price or payment reforms that change margins
Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease
A multicenter randomized trial found that community health worker support produced modest but durable improvements in health-related quality of life for young adults with sickle cell disease during transition to adult care, whereas a mobile
Modernizing AML Trial Eligibility Boosts Enrollment and Equity: Safety-Based Criteria Could Double Participation
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t
Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi
CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an
AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor
Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014
The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s
Venetoclax Dose Escalation Triggers a Rapid BAFF–BCL-2 Survival Axis in CLL: Implications for Resistance and Combination Strategies
Early venetoclax therapy rapidly induces a BAFF-driven upregulation of prosurvival BCL-2 family proteins in surviving CLL cells, suggesting homeostatic cytokine signaling limits depth and durability of response and identifying BAFF/MCL-1 pa
Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters
Large trial and real‑world data show fixed‑duration venetoclax‑obinutuzumab delivers high response and durable PFS in fit and unfit CLL patients; maintaining adequate venetoclax dose intensity appears important for MRD and long‑term outcome
Long-term Outcomes in Congenital TTP: Registry Data Show Prophylactic Plasma Reduces Clinical Events but Symptoms and Product Burden Persist
UK registry follow-up of 104 congenital TTP patients shows regular plasma prophylaxis lowers acute episodes and end‑organ events, but residual symptoms and plasma-related issues drive many patients to recombinant ADAMTS13.
DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
In older adults (≥60 years) with non‑adverse‑risk AML enrolled in NCRI AML18, daunorubicin/cytarabine plus fractionated gemtuzumab (DAGO2) produced higher early MRD‑negative CR rates and superior 3‑year EFS and OS versus CPX‑351, with parti
DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc
Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
Preclinical work shows that combining the BCL‑2 inhibitor venetoclax with the FLT3 inhibitor gilteritinib produces deep, reproducible anti‑leukemia activity in FLT3‑mutant, BCL11B‑activated lineage‑ambiguous leukemias. BH3 profiling and sin
Allogeneic HCT in AYA ALL in CR2: MRD-Negativity and Low HCT‑CI Drive Durable Remissions — Dual‑Center Real‑World Outcomes
In 164 adolescents and young adults with ALL transplanted in second remission, 3‑year overall survival was 53% and progression‑free survival 46%. MRD positivity and HCT‑Comorbidity Index >3 predicted worse outcomes; female‑to‑male donor pai
Browse by specialty
Open language-specific specialty feeds and department pages.